NCCN Flash Updates: NCCN Templates^® Updated for Vulvar Cancer and Uterine Cancer

NCCN has published updates to the NCCN Chemotherapy Order Templates (NCCN Templates^®) for Vulvar Cancer to reflect the currently published NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines^®) for Vulvar Cancer v2.2020.

• The following NEW NCCN Templates^® have been published:
  • VUL15: Entrectinib
  • VUL16: Larotrectinib
• Changes to the Chemotherapy Regimen section have been made to the following templates:
  • VUL2: CISplatin/Fluorouracil with Concurrent Radiation
  • VUL4: CISplatin
  • VUL5: CISplatin/VinORELBine
  • VUL6: PACLitaxel/CISplatin
  • VUL7: CARBOplatin
  • VUL8: PACLitaxel/CARBOplatin
  • VUL9: Erlotinib
  • VUL10: PACLitaxel
  • VUL11: Gemcitabine/CISplatin
  • VUL12: Pembrolizumab
• Changes to the Indication section have been made to the following templates:
  • VUL1: CISplatin with Concurrent Radiation
  • VUL2: CISplatin/Fluorouracil with Concurrent Radiation
  • VUL3: Fluorouracil/MitoMYcin with Concurrent Radiation
  • VUL12: Pembrolizumab
• Changes to the References section have been made to the following template:
  • VUL12: Pembrolizumab
• The following myeloid growth factor note for templates with a febrile neutropenia risk of “intermediate” has been revised in the Supportive Care section:
  • CSFs may be considered for primary prophylaxis based on the febrile neutropenia (FN) risk of the chemotherapy regimen. For more information on prophylaxis of FN and a list of appropriate agents, refer to the Myeloid Growth Factors algorithms in the NCCN Guidelines for Hematopoietic Growth Factors and Appendix C to the NCCN Templates.
  • Affected templates:
    • VUL6: PACLitaxel/CISplatin
    • VUL14: PACLitaxel/CISplatin + Bevacizumab
• Drug information notes for the following medications have been updated in the Supportive Care, Monitoring and Hold Parameters, and/or Safety Parameters and Special Instructions sections:
  • Bevacizumab
  • CISplatin
  • Erlotinib
  • Fluorouracil
  • Gemcitabine
  • MitoMYcin
  • PACLitaxel
  • VinORELBine

NCCN has published updates to the NCCN Templates for Uterine Neoplasms to reflect the currently published NCCN Guidelines^® for Uterine Neoplasms v2.2020.

• Changes to the Chemotherapy Regimen and References sections have been made to the following template:
  • UTE19: Pembrolizumab

For the complete updated versions of the NCCN Guidelines, NCCN Guidelines with NCCN Evidence Blocks™, the NCCN Drugs & Biologics Compendium (NCCN Compendium^®), the NCCN Biomarkers Compendium^®, the NCCN Chemotherapy Order Templates (NCCN Templates^®), the NCCN Radiation Therapy Compendium™, and the NCCN Imaging Appropriate Use Criteria (NCCN Imaging AUC™), please visit NCCN.org.

To view the NCCN Guidelines for Patients^®, please visit NCCN.org/patientguidelines.

Free NCCN Guidelines apps for iPhone, iPad, and Android devices are now available! Visit NCCN.org/apps.

About NCCN Flash Updates™

NCCN Flash Updates™ is a subscription service from NCCN that provides timely notification of updated and new information appearing in the NCCN Guidelines, the NCCN Compendium^®, and other NCCN Content.

Subscribe to NCCN Flash Updates™

Please note: The NCCN Third Party Content FTP site: ftp://ftp1.nccn.org/ThirdPartyContent/ has been updated. Licensees are solely responsible for obtaining permission from such third party to use any such Third Party Content in the Permitted Works.

Access information on permissions and licensing of NCCN Content

Users may unsubscribe from Flash Updates at any time by contacting us. NOTE: The subscription fee for NCCN Flash Updates™ is non-refundable.